Our goal is to have a meaningful impact on skin disease and particularly skin cancers: the world's most common cancers, by delivering breakthrough solutions to patients.

Peplin, Inc. has approximately 10.3 million shares of common stock on  issue owned by over 3,000 shareholders. Most shareholders hold their shares of common stock in the form of Chess Depository Interests (CDIs) which are listed on the Australian Securities Exchange (ASX:PLI). The company is headquartered in Emeryville, California with operations in Brisbane, Queensland, Australia and a manufacturing facility in Southport, Queensland.

Peplin is developing new products which represent a significant advance in the treatment of the most common form of skin cancer.

Peplin's core technology is a novel class of naturally occurring compounds which show significant potential as anti-cancer agents for a wide range of human cancers. The lead compound in this technology (PEP005 (ingenol mebutate)) has demonstrated significant promise in phase II clinical trials as a topical agent for the treatment of actinic (solar) keratosis (AK), a common pre-cancerous lesion, and basal cell carcinoma (BCC), the most common form of skin cancer. Peplin believes the unique benefits of PEP005 (ingenol mebutate) Gel for AK and BCC may include a very short course of therapy and a transient and favourable side effect profile. Peplin has extensive international patent coverage over its technologies.